Eloralintide

LY3841136

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Long-acting selective amylin receptor agonist; synthetic peptide analogue of amylin, engineered for once-weekly dosing and reported to have little direct calcitonin-receptor activity
Mechanism: Activates amylin receptors in the brainstem and hypothalamus to increase fullness and reduce food intake, with a slower gastric emptying effect
Routes studied: Subcutaneous once weekly
Dose range reported: Phase 2: weekly doses ranging from about 1 mg to 9 mg, some with titration, for 48 weeks †. No approved dose exists; community-reported use is minimal and unvalidated
Half-life: Supports once-weekly dosing (several days) †
Storage: Investigational; grey-market lyophilised material, where present, follows standard peptide handling (refrigerate, protect from light)
Regulatory status: Investigational; not approved anywhere. Phase 3 programme under way †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Eloralintide is Eli Lilly's amylin analogue, and the one that, in 2025, produced the most striking data yet for the class. Where pramlintide (profile 65) gave a few percent weight loss with three injections a day, and cagrilintide alone gave about 10–11% at 26 weeks, eloralintide's phase 2 reported weight loss approaching the lower end of what tirzepatide achieves, with a side-effect profile that looked gentler.

Lilly describes it as "selective" for the amylin receptor — meaning it activates the calcitonin receptor + RAMP complexes that constitute amylin receptors, with less activity at the unpaired calcitonin receptor than compounds such as cagrilintide (sometimes called dual amylin and calcitonin receptor , or DACRAs). Whether that selectivity explains the tolerability is a hypothesis.

2How it's thought to work

Satiety signalling. mimics meal-related amylin release to the area postrema and hypothalamus, reducing meal size and overall intake. The pathway is distinct from GLP-1, which is why the two are candidates for combination.

Gastric emptying and post-meal glucagon. slowed and suppressed, respectively.

Energy expenditure and leptin sensitivity. amylin agonism has been reported to restore leptin responsiveness in obese rodents; a contribution to sustained weight loss is plausible but not demonstrated for eloralintide.

Receptor selectivity. by minimising calcitonin-receptor activity, Lilly aims to avoid effects on calcium and bone and possibly nausea; this is a design rationale more than a demonstrated outcome.

A long-acting amylin receptor agonist in trials for obesity, pursued because amylin reduces intake through a different pathway from GLP-1.Schematic — not to scale

3What the research shows

Graded A (phase 2)

Weight loss in adults with obesity or overweight

A 48-week randomised, placebo-controlled phase 2 trial (n≈263) tested several weekly dose arms. Lilly reported mean weight reductions ranging from about 9.5% to 20.1% across arms versus about 0.4% with placebo at 48 weeks, with weight still declining at study end in the higher arms. Gastrointestinal adverse events were described as mostly mild to moderate and less frequent than typically seen with GLP-1 , with discontinuation for adverse events in the low single digits to high single digits depending on arm. Results were presented at EASD 2025 and published in The Lancet †. A single phase 2 earns an A on this site's grading because it is a published human , but it is one trial, in one population, without long-term follow-up.

Combination with tirzepatide

A phase 1b/2 study of eloralintide added to tirzepatide in adults with obesity has been run; Lilly has reported additional weight loss over tirzepatide alone in early data †. This is the obvious commercial direction.

Not gradedgrade pending

Type 2 diabetes

A phase 2 in type 2 diabetes with obesity has been conducted or is ongoing †. Amylin analogues improve post-meal glucose, so a glycaemic benefit is expected.

Not gradedongoing

Phase 3

Lilly announced phase 3 trials of eloralintide alone and in combination †. No phase 3 results exist as of this review.

Lean mass preservation

Claimed as a potential class advantage; not yet shown in published DEXA data for eloralintide.

4Reported side effects and interactions

Literature-reported

nausea, vomiting, diarrhoea, constipation and decreased appetite at lower rates than seen in GLP-1 trials of similar weight loss †; injection-site reactions; fatigue. No serious safety signal reported publicly from phase 2. Exposure totals a few hundred people for under a year.

Community-reported

very limited; grey-market "eloralintide" has appeared since the 2025 data, and product identity cannot be assumed. Reports of appetite suppression with less nausea than semaglutide echo the trial narrative but are unverifiable.

Theoretical (class). delayed oral drug absorption; hypoglycaemia only with insulin or sulfonylureas; calcitonin-receptor effects on calcium and bone over the long term (eloralintide's selectivity is intended to minimise this); anti-drug antibodies †. Pregnancy: not studied.

Interactions. additive with GLP-1 and GLP-1/GIP agonists (intended); none otherwise established.

Markers researchers commonly monitor

No compound-specific markers are established; based on the trial protocols and class physiology:

Marker	Why it's watched
Weight, waist and body composition (DEXA/bioimpedance)	lean-mass preservation is the class's main unproven claim; measure rather than assume.
HbA1c and fasting glucose	amylin analogues lower post-meal glucose; relevant for anyone with prediabetes or diabetes.
Lipid panel and blood pressure	expected to improve with weight loss.
Serum calcium	a baseline is reasonable given the calcitonin-receptor family, even though selectivity is claimed.
eGFR and creatinine	dehydration during GI effects.
Resting heart rate	amylin analogues appear to raise heart rate less than GLP-1 agonists; worth confirming individually.
CBC and CMP	general baseline for an investigational injected compound.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Investigational product supplied in trials as a liquid for injection. Grey-market material is , typically in 5 mg or 10 mg vials. Trial doses are in milligrams weekly and were titrated over weeks; concentration after and unit confusion are the practical risks. Reconstitute with , swirl gently, refrigerate, protect from light.

Open in calculator, pre-loaded →

6Commonly studied alongside

Tirzepatide (Lilly's intended combination). Class comparators: cagrilintide/CagriSema, petrelintide, pramlintide. Community discussion pairs it with semaglutide or tirzepatide in imitation of CagriSema; only the tirzepatide combination has any trial data.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved; investigational (phase 3). Not permitted for compounding
European Union	Not authorised; investigational
United Kingdom	Not licensed
Australia	Not approved
South Africa	Not registered
Sport	Not specifically listed by WADA; as a non-approved substance it falls under S0 †

8Open questions

Will the phase 2 effect size and tolerability hold in phase 3 and beyond 48 weeks?
How much does eloralintide add to tirzepatide, and at what tolerability cost?
Is lean mass genuinely better preserved than with GLP-1 ?
Long-term effects on bone and calcium handling, given the receptor family.
Weight regain after stopping — unknown for the entire amylin class except pramlintide.

9References

1Eli Lilly (2025). Eloralintide phase 2 results in adults with obesity or overweight — presented at EASD 2025; published in Lancet [verify authors, title and figures]. PubMed
2Eli Lilly (2025). Eloralintide in combination with tirzepatide — phase 1b/2 announcement [verify]. PubMed
3ClinicalTrials.gov. Phase 2 and phase 3 trials of LY3841136 (eloralintide) [verify identifiers]. PubMed
4Hay DL et al. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. PubMed · DOI
5Boyle CN, Lutz TA, Le Foll C (2018). Amylin — its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. PubMed · DOI

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.